Rituximab primarily targets an intra-clonal BCR signaling proficient CLL subpopulation characterized by high CD20 levels
Language English Country Great Britain, England Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
30030508
DOI
10.1038/s41375-018-0211-0
PII: 10.1038/s41375-018-0211-0
Knihovny.cz E-resources
- MeSH
- Antigens, CD20 metabolism MeSH
- Biomarkers MeSH
- Antibody-Dependent Cell Cytotoxicity immunology MeSH
- Leukemia, Lymphocytic, Chronic, B-Cell drug therapy immunology metabolism pathology MeSH
- Cytotoxicity, Immunologic MeSH
- Phenotype MeSH
- Complement System Proteins immunology MeSH
- Humans MeSH
- Tumor Cells, Cultured MeSH
- Tumor Microenvironment drug effects immunology MeSH
- Antineoplastic Agents, Immunological pharmacology therapeutic use MeSH
- Receptors, Antigen, B-Cell metabolism MeSH
- Rituximab pharmacology therapeutic use MeSH
- Signal Transduction drug effects MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Antigens, CD20 MeSH
- Biomarkers MeSH
- Complement System Proteins MeSH
- Antineoplastic Agents, Immunological MeSH
- Receptors, Antigen, B-Cell MeSH
- Rituximab MeSH
References provided by Crossref.org
In Vitro and In Vivo Models of CLL-T Cell Interactions: Implications for Drug Testing
FoxO1-GAB1 axis regulates homing capacity and tonic AKT activity in chronic lymphocytic leukemia
Genetic and Non-Genetic Mechanisms of Resistance to BCR Signaling Inhibitors in B Cell Malignancies
The regulation and function of CD20: an "enigma" of B-cell biology and targeted therapy
